Robert Davis - Intracellular Senior Vice President and Chief Scientific Officer
| ITCI Stock | USD 127.00 0.02 0.02% |
President
Mr. Robert E. Davis is Ph.D., is the Senior Vice President and Chief Scientific Officer of IntraCellular Therapies, Inc. Mr Davis previously served as President and CEO of 3D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at ParkeDavis Pharmaceutical Research, WarnerLambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimers disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease since 2015.
| Age | 74 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.0745) % which means that it has lost $0.0745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.099) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Anastasios Konidaris | Amneal Pharmaceuticals, Class | 58 | |
| Stephen Carey | ANI Pharmaceuticals | 54 | |
| Scott Dreyer | Collegium Pharmaceutical | 53 | |
| Peter Boyd | Aquestive Therapeutics | 59 | |
| Michael Landine | Alkermes Plc | 70 | |
| Ryan Spencer | Dynavax Technologies | 47 | |
| Daniel Barber | Aquestive Therapeutics | 49 | |
| David Gaffin | Alkermes Plc | 52 | |
| Andrew Boyer | Amneal Pharmaceuticals, Class | 59 | |
| Joseph Greer | Amneal Pharmaceuticals, Class | N/A | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Nikita Shah | Amneal Pharmaceuticals, Class | 46 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Stephen Manzano | Amneal Pharmaceuticals, Class | 55 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Joseph Todisco | Amneal Pharmaceuticals, Class | 45 | |
| Sanjay Jain | Amneal Pharmaceuticals, Class | N/A | |
| Robert Janssen | Dynavax Technologies | 70 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
Management Performance
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO, Fin | ||
| Juan MD, Vice Relations | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Suresh MD, Executive Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Willie MD, Senior Development | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Michael JD, General VP | ||
| Sanjeev Narula, Executive CFO | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Lawrence CPA, CFO, Finance | ||
| John Condon, General President | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 12.51 B | ||||
| Shares Outstanding | 106.24 M | ||||
| Shares Owned By Insiders | 2.33 % | ||||
| Shares Owned By Institutions | 95.99 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Earning | (6.56) X |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.